Charles Fuchs, MD: First-Line Treatments in Unresectable Colon Cancer
What are the first-line treatments for patients diagnosed with advanced, unresectable colon cancer?
For a newly-diagnosed patient with metastatic colorectal caner, there are several options. Firstly, with regard to the chemotherapy backbone, one could either consider FOLFOX, namely an oxaliplatin-based regimen, or FOLFIRI, an irinotican-based regimen. What we know from the literature is that those two chemotherapy combinations have equivalent efficacy. They have some differences in toxicities, but both relatively well-tolerated and perfectly reasonable frontline regimens.
My own preference has historically been to start with FOLFOX, but I think FOLFIRI is an excellent regimen. With regard to the biologics that should be added to these regimens, and I think there's compelling evidence to add a biologic, bevacizumab is a very appropriate addition. That is the drugs that target the EGFR pathway have considering efficacy and there are several now approved. The combination of FOLFOX or FOLFIRI and bevacizumab is reasonable.
Unresectable Colon Cancer: Case 1
68-year-old man was diagnosed with advanced, unresectable colon cancer has just started treatment with FOLFIRI plus bevacizumab.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Study Finds Susceptibility Gene Variations by Race/Ethnicity in Early-Onset CRC
February 20th 2024In an interview with Targeted Oncology, Andreana N. Holowatyj, PhD, MSCI, discussed data from a study which found racial and ethnic differences in susceptibility genes for early-onset colorectal cancer, suggesting current multigene panel tests may not be accurate for diverse populations.
Read More
